Paraproteinemia

From

Jump to: navigation, search

Contents

More Specific Terms

Introduction

Classification

  • 5 clinical groups:

Epidemiology

Pathology

Genetics

Clinical-manifestations

  • see classification for different patterns
  • cutaneous psoriasis
  • asymmetric involvement of a small number of joints early
  • involvement of DIP joints in hands & feet

Laboratory

Radiology

  • distal interphalageal joint involvement

Complications

Differential-diagnosis

Management

  • not recommended (NICE)

More General Terms

Additional Terms

Internet Database

OMIM: [1]

References

  1. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 866
  2. Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 15, 16, 17. American College of Physicians, Philadelphia 1998, 2006, 2009, 2012, 2015
  3. Weiner S, In: UCLA Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 12-15, 2001
  4. Zenz R et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005 Sep 15; 437:369-75. PMID: [2]
  5. Gottlieb A et al, Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008 May;58(5):851-64 PMID: [3]
  6. Ritchlin CT, Kavanaugh A, Gladman DD et al Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009 Sep;68(9):1387-94 PMID: [4]
  7. Taylor W, Gladman D, Helliwell P et al Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug;54(8):2665-73. PMID: [5]
  8. Mease PJ et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014 Jun 12; 370:2295 PMID: [6]
  9. Ogdie A et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population- based cohort study. Ann Rheum Dis 2015 Feb; 74:326. <PubMed> PMID: [7] <Internet> [8]
  10. Coates LC, Conaghan PG, Emery P et al Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum. 2012 Oct;64(10):3150-5. PMID: [9]
  11. National Guideline Clearinghouse
    - Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. American Academy of Dermatology ngc-guideline: [10]
    - Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. American Academy of Dermatology ngc-guideline: [11]
    - Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. American Academy of Dermatology ngc-guideline: [12]
    - Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4: guidelines of care for the management and treatment of psoriasis with traditional systemic agents. American Academy of Dermatology ngc-guideline: [13]
    - Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 5: guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. American Academy of Dermatology ngc-guideline: [14]
    - Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. American Academy of Dermatology ngc-guideline: [15]
    - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. National Institute for Health and Clinical Excellence ngc-guideline: [16]
    - Diagnosis and management of psoriasis and psoriatic arthritis in adults. A national clinical guideline. Scottish Intercollegiate Guidelines Network (SIGN) ngc-guideline: [17]
    - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. National Institute for Health and Clinical Excellence (NICE) ngc-guideline: [18]
    - Ustekinumab for treating active psoriatic arthritis. National Institute for Health and Clinical Excellence (NICE) ngc-guideline: [19]

Personal tools